HYMAN IP LAW
Biotechnology Patent and Licensing Services
Patent Experience

Larry Hyman has written, prosecuted, and obtained scores of U.S. patents  and directed the prosecution of patent applications in jurisdictions around the world. 


U.S. patents that have issued from applications written by Mr. Hyman include: 


U.S. Patent No. 9,119,837.  Use of sEH inhibitors as analgesics.

U.S. Patent No. 9,115,196.  Antibodies and immunotoxins that target human glycoprotein NMB

U.S. Patent No. 9,089,601.  Pre- and intra- operative imaging of bladder cancer.

U.S. Patent No. 8,907,060.  Mutated Pseudomonas exotoxins with reduced antigenicity.

U.S. Patent No. 8,871,906.  Deletions in domain II of pseudomonas exotoxin a that remove immunogenic epitopes

U.S. Patent No. 8,809,502.  Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells.

U.S. Patent No. D710,514.   Light therapy device.

U.S. Patent No. 8,725,225.  Intraoperative imaging of renal cortical tumors and cysts.

U.S. Patent No. 8,513,302.  Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids.

U.S. Patent No. 8,445,216.  Antibodies and immunotoxins that target human glycoprotein NMB.

U.S. Patent No. 8,399425.   Alleviating neuropathic pain with EETs and sEH inhibitors.

U.S. Patent No. 8,389,030.  Nematicides from Juglandaceae and methods of use thereof.

U.S. Patent No. 8,263,651. Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by PBR, CB2, and NK2 receptors.

U.S. Patent No. 8,242,170.  Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy 

U.S. Patent No. 8,202,507.  Assay for vitamin B12 absorption and method of making labeled vitamin B12.

U.S. Patent No. 8,198,063.  Rapid deglycosylation of glycoproteins.

U.S. Patent No. 8,124,085.  Bispecific binding agents for modulating biological activity.

U.S. Patent No. 8,084,220.  Methods for detecting the presence of expanded CGG repeats in the FMR1 gene 5' untranslated region.

U.S. Patent No. 8,039,593.  Antibodies and immunotoxins that target human glycoprotein NMB.

U.S. Patent No. 7,982,011.  Mutated anti-CD22 antibodies and immunoconjugates.

U.S. Patent No. 7,968,298. Use of herpesviruses, herpesvirus proteins and nucleic acids encoding the proteins to inhibit CCR5-tropic HIV-1 infection and replication.

U.S. Patent No. 7,951,831. Use of inhibitors of soluble epoxide hydrolase to synergize activity of COX and 5-LOX inhibitors.

U.S. Patent No. 7,927,635. Nematicides from Juglandaceae and methods of use thereof.

U.S. Patent No. 7,855,053. Methods for detecting the presence of expanded CGG repeats in the FMR1 gene 5' untranslated region.

U.S. Patent No. 7,777,019. Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells.

U.S. Patent No. 7,691,630. Compositions for protecting plants from pathogens.

U.S. Patent No. 7,666,591. Single stranded DNA binding proteins from Archaea and uses therefor.

U.S. Patent No. 7,541,040. Chimeric molecule for the treatment of TH2-like cytokine mediated disorders.   

U.S. Patent No. 7,521,054. Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the Fv to lower the isoelectric point.

U.S. Patent No. 7,517,849. Inhibition of ABC transporters by transmembrane domain analogs.

U.S. Patent No. 7,470,775. Anti-CD30 stalk and anti-CD30 antibodies suitable for use in immunotoxins.

U.S. Patent No. 7,404,954. Methods of targeting agents to cells expressing the polymeric immunoglobulin receptor.

U.S. Patent No. 7,399,827. Page-4, an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor.

U.S. Patent No. 7,368,110.  Antibodies, including Fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use.

U.S. Patent No. 7,355,012.  Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells.

U.S. Patent No. 7,193,054. Nanofabrication using actin filaments.

U.S. Patent No. 7,129,332.  Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof.

U.S. Patent No. 7,081,518. Anti-mesothelin antibodies having high binding affinity.

U.S. Patent No. 7,060,486. Inhibition of sulfate-reducing-bacteria-mediated degradation using bacteria which secrete antimicrobials.   

U.S. Patent No. 7,052,911. Methods of increasing plant yield.

U.S. Patent No. 7,052,703. T-cell receptor gamma alternate reading frame protein (TARP), and uses thereof. 

U.S. Patent No. 6,905,822.  Methods of diagnosing multidrug resistant tuberculosis.

U.S. Patent No. 6,869,628.  Methods and formulations for providing gloss coatings to foods and for protecting nuts from rancidity.

U.S. Patent No. 6,855,810. Ligands directed to the non-secretory component, non-stalk region of plgR and methods of use thereof.

U.S. Patent No. 6,852,832. Single stranded DNA binding proteins from archaea.

U.S. Patent No. 6,720,167. Insecticidal bacteria, and methods for making and using them.

U.S. Patent No. 6,696,064. Methods of protecting vasculature from damage by diphtheria toxin-and pseudomonas toxin-based immunotoxins during therapy.

U.S. Patent No. 6,630,197. Inhibition of sulfate-reducing-bacteria-mediated degradation using bacteria which secrete antimicrobials.

U.S. Patent No. 6,582,961. Methods of protecting plants from pathogens. 

U.S. Patent No. 6,570,069. Nucleic acids encoding plant inhibitors of apoptosis and transgenic cells and plants expressing them.  

U.S. Patent No. 6,511,824. Selective assay for determining the identity of live microorganisms in a mixed culture.

U.S. Patent No. 6,402,914. In-situ loader for electrophoretic gels.

U.S. Patent No. 6,191,103. Methods for enhancing thrombolysis in a mammal.



 
HYMAN IP LAW
555  California Street, Suite 4925
San Francisco, CA 94104-1717

Phone: 415-440-3100
Fax:     415-440-3131
 
Email: lhyman (at) hymaniplaw.com

Web:  www.hymaniplaw.com


Home About Larry HymanIn the NewsServicesPatent ExperienceLicensing and Transactional ExperiencePortfolio Evaluation and Opinion WorkContact